Comparison of efficacy between incretin-based therapies for type 2 diabetes mellitus
BMC Medicine 2012, 10:152 (30 November 2012)
This article is part of a collection on
Metabolism, diet and...
Melanie Davies and colleagues review the differences between two incretin-based therapies for type 2 diabetes, glucagon-like peptide agonists and dipeptidyl peptidase 4 inhibitors, and recommend effective and safe individualized treatment.